泊沙康唑与伊布替尼相互作用无法通过错峰给药避免:如何优化伊布替尼剂量
结论建议泊沙康唑治疗期间伊布替尼日剂量不应超过70 mg。
要点
- 泊沙康唑使伊布替尼AUC和Cmax平均增加约10倍和8倍。
- 早晚泊沙康唑对伊布替尼暴露的影响无显著差异。
- 错峰12小时给药不能避免相互作用,需限制伊布替尼剂量。
核心结论
- 泊沙康唑使伊布替尼暴露量增加约10倍,错峰12小时给药无法避免此相互作用。
研究设计与样本
- 受试者接受泊沙康唑300 mg早晨或晚上重复给药或安慰剂,并在前次给药后9 AM、1或12小时单次服用伊布替尼30、70或140 mg。
主要发现
- 早晨泊沙康唑使伊布替尼剂量校正AUC0-∞增加9.5倍(90% CI 6.3-14.3,P < 0.001),Cmax增加8.5倍(90% CI 5.7-12.8,P < 0.001)。
- 晚上泊沙康唑使伊布替尼AUC0-∞增加10.3倍(90% CI 6.7-16.0,P < 0.001),Cmax增加8.2倍(90% CI 5.2-13.2,P < 0.001)。
- 泊沙康唑对伊布替尼半衰期无显著影响,但显著降低代谢物PCI-45227与伊布替尼AUC0-∞比值。
- 早晨与晚上泊沙康唑阶段之间伊布替尼药代动力学无显著差异。
关键数值与推荐
- 泊沙康唑治疗期间,伊布替尼日剂量一般不应超过70 mg,以避免潜在毒性全身浓度。
临床怎么用
- 临床使用泊沙康唑时,应将伊布替尼日剂量限制在70 mg以内。
- 错峰12小时给药不能规避相互作用,无需采用此策略。
局限性
- 研究在健康受试者中进行,结论外推至患者需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Ibrutinib is used in the treatment of certain B-cell malignancies. Due to its CYP3A4-mediated metabolism and highly variable pharmacokinetics, it is prone to potentially harmful drug-drug interactions. METHODS: In a randomized, placebo-controlled, three-phase crossover study, we examined the effect of the CYP3A4-inhibiting antifungal posaconazole on ibrutinib pharmacokinetics. Eleven healthy participants ingested repeated doses of 300 mg of posaconazole either in the morning or in the evening, or placebo. A single dose of ibrutinib (30, 70 or 140 mg, respectively) was administered at 9 AM, 1 or 12 h after the preceding posaconazole/placebo dose. RESULTS: On average, morning posaconazole increased the dose-adjusted geometric mean area under the plasma concentration-time curve from zero to infinity (AUC0-∞ ) and peak plasma concentration (Cmax ) of ibrutinib 9.5-fold (90% confidence interval [CI] 6.3-14.3, P < 0.001) and 8.5-fold (90% CI 5.7-12.8, P < 0.001), respectively, while evening posaconazole increased those 10.3-fold (90% CI 6.7-16.0, P < 0.001) and 8.2-fold (90% CI 5.2-13.2, P < 0.001), respectively. Posaconazole had no significant effect on the half-life of ibrutinib, but substantially reduced the metabolite PCI-45227 to ibrutinib AUC0-∞ ratio. There were no significant differences in ibrutinib pharmacokinetics between morning and evening posaconazole phases. CONCLUSIONS: Posaconazole increases ibrutinib exposure substantially, by about 10-fold. This interaction cannot be avoided by dosing the drugs 12 h apart. In general, a 70-mg daily dose of ibrutinib should not be exceeded during posaconazole treatment to avoid potentially toxic systemic ibrutinib concentrations.
引用
- Olkkola AM, Tapaninen T, Tornio A, et al. Posaconazole-ibrutinib interaction cannot be avoided by staggered dosing: How to optimize ibrutinib dose during posaconazole treatment. Br J Clin Pharmacol. 2023. PMID: 37872104. doi:10.1111/bcp.15932
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。